WORLD LEADING PARASITOLOGY AND MYCOLOGY TEST KITS
RAPID LATERAL FLOW TEST FOR BRUCELLA CANIS NOW AVAILABLE
Q-TOX FACTOR-X ACTIVATOR RVV-X NOW AVAILABLE
COST EFFECTIVE VETERINARY DIAGNOSTICS NOW AVAILABLE
Featured Products
Our Product Ranges
Recieve our latest news
Sign up to our newsletterOur Company
With over 30 years of trading experience, Quadratech Diagnostics Limited has always been and remains committed to providing the highest quality state-of-the-art medical diagnostic and research products. Since the company was founded in 1990, we have expanded to encompass the following main areas: Haemostasis, Antigens, Antibodies and Toxins, Rapid and POC Tests, Parasitology and Veterinary.
Quadratech Diagnostics Limited is a corporate member of the Institute of Biomedical Scientists (IBMS) and the British Society for Haemostasis and Thrombosis (BSHT). We are a recognised supplier to the UK National Health Service (NHS), the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups. Quadratech Diagnostics Limited became incorporated as a limited company in 1998 and is ISO 9001:2015 certified.
Our Product Brands
Latest News
Quadratech Diagnostics Launches QD-SUB-366 – Activated Protein C and FXI Chromogenic Substrate
We are delighted to announce the global launch of QD-SUB-366 – Activated Protein C and FXI Chromogenic Substrate, the first chromogenic substrate from our new QD-TECH range. Developed through close collaboration with leading scientists, clinicians, and ISO/FDA-registered European manufacturers, QD-TECH reagents are tailored for use in clinical laboratories, research centres, and the pharmaceutical industry. QD-SUB-366 […]
Haemostasis March 2025 News
Our round-up of the latest developments from across the haemostasis industry for March 2025. REGULATORY Genentech’s TNKase (tenecteplase, tissue plasminogen activator) was approved by the FDA for the treatment of acute ischemic stroke (AIS) in adults, administered as a single 5-second intravenous (IV) bolus (3 Mar) Sanofi / Alnylam’s Qfitlia (fitusiran, antithrombin RNAi) was approved by […]
Haemostasis April 2025 Journal Club
Keep informed about evolving science and clinical practice with our March 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis. PERSPECTIVES & REVIEWS Ellsworth P, Chen SL, Jones LA, et al. Acquired hemophilia A: a narrative review and management approach in the emicizumab era. J Thromb Haemost. 2025;23(3):824-835. doi:10.1016/j.jtha.2024.09.04 Reyes Ruiz A, Bhale […]
